These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
382 related articles for article (PubMed ID: 29167001)
1. [Association between the ALK Gene Status and the Efficacy of First-line Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma]. Chen M; Cao H; Ji Y; Mao Y; Shen S; Li X Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):732-736. PubMed ID: 29167001 [TBL] [Abstract][Full Text] [Related]
2. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements. Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations. Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798 [TBL] [Abstract][Full Text] [Related]
4. [Association between the HER2 Gene Status and the Efficacy of First-line Pemetrexed Combined with Platinum Chemotherapy in Patients with Advanced Lung Adenocarcinoma]. Li P; Li B; Shi Y; Zhang F; Shen S; Li X Zhongguo Fei Ai Za Zhi; 2019 Mar; 22(3):137-142. PubMed ID: 30909992 [TBL] [Abstract][Full Text] [Related]
5. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. Camidge DR; Kono SA; Lu X; Okuyama S; Barón AE; Oton AB; Davies AM; Varella-Garcia M; Franklin W; Doebele RC J Thorac Oncol; 2011 Apr; 6(4):774-80. PubMed ID: 21336183 [TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants. Cha YJ; Kim HR; Shim HS J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333 [TBL] [Abstract][Full Text] [Related]
7. MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations. Shi SB; Wang M; Tian J; Li R; Chang CX; Qi JL Transl Res; 2016 Apr; 170():1-7. PubMed ID: 26687391 [TBL] [Abstract][Full Text] [Related]
8. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756 [TBL] [Abstract][Full Text] [Related]
9. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718 [TBL] [Abstract][Full Text] [Related]
10. Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy. Song Z; Su H; Zhang Y Cancer Med; 2016 Oct; 5(10):2688-2693. PubMed ID: 27544536 [TBL] [Abstract][Full Text] [Related]
11. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma. Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518 [TBL] [Abstract][Full Text] [Related]
12. Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment. Zhou J; Zheng J; Zhang X; Zhao J; Zhu Y; Shen Q; Wang Y; Sun K; Zhang Z; Pan Z; Shen Y; Zhou J BMC Cancer; 2018 Jan; 18(1):10. PubMed ID: 29298713 [TBL] [Abstract][Full Text] [Related]
13. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer. Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691 [TBL] [Abstract][Full Text] [Related]
14. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype. Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer. Jo J; Kim SH; Kim YJ; Lee J; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Chung JH; Jeon YK; Lee JS Yonsei Med J; 2018 Mar; 59(2):202-210. PubMed ID: 29436187 [TBL] [Abstract][Full Text] [Related]
16. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Shaw AT; Varghese AM; Solomon BJ; Costa DB; Novello S; Mino-Kenudson M; Awad MM; Engelman JA; Riely GJ; Monica V; Yeap BY; Scagliotti GV Ann Oncol; 2013 Jan; 24(1):59-66. PubMed ID: 22887466 [TBL] [Abstract][Full Text] [Related]
17. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. Lee JO; Kim TM; Lee SH; Kim DW; Kim S; Jeon YK; Chung DH; Kim WH; Kim YT; Yang SC; Kim YW; Heo DS; Bang YJ J Thorac Oncol; 2011 Sep; 6(9):1474-80. PubMed ID: 21642865 [TBL] [Abstract][Full Text] [Related]
18. [Efficacy of chemotherapy after EGFR-TKIs resistance in 191 patients with Unknow EGFR gene mutation in advanced lung adenocarcinoma]. He P; Wang Y; Yang S; Yu S; Wang Z; Li J; Wang B; Hao X; Wang H; Hu X; Zhang X; Shi Y Zhongguo Fei Ai Za Zhi; 2013 Oct; 16(10):529-34. PubMed ID: 24113006 [TBL] [Abstract][Full Text] [Related]
19. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma. Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463 [TBL] [Abstract][Full Text] [Related]